Atropine

Overview

Atropine is a prototype antimuscarinic (anticholinergic) agent widely used in dogs and cats for cardiovascular support, anesthetic management, and as an antidote for cholinergic agents and toxins. It competitively inhibits acetylcholine at postganglionic parasympathetic receptors, producing predictable, dose-related anticholinergic effects.

In small animal practice, systemic atropine is most commonly used to treat or prevent vagally mediated bradycardia, particularly during anesthesia or procedures associated with increased vagal tone. Its routine prophylactic use has declined, and treatment of clinically relevant bradyarrhythmias as they occur is generally preferred.

Atropine also plays an important role as an antidote for cholinergic toxicoses and for mitigating adverse muscarinic effects associated with certain therapeutic drugs. In dogs, a positive heart rate response to atropine may help predict vagally mediated causes of bradyarrhythmia and guide further medical management.

Mechanism of Action (MOA): Atropine competitively blocks muscarinic acetylcholine receptors at parasympathetic neuroeffector sites. At low to moderate doses, it reduces salivary and respiratory secretions and increases heart rate, although a brief initial bradycardia may occur. Higher doses decrease gastrointestinal and urinary tract motility and produce mydriasis and cycloplegia.

Atropine has a rapid onset of action after parenteral administration and a relatively short duration compared with some other anticholinergic agents. It crosses the blood–brain barrier and placenta, is metabolized by the liver, and is eliminated primarily in the urine. Compared with glycopyrrolate, atropine has a faster onset, shorter duration of action, and produces more pronounced tachycardia.

Indications

Atropine is used systemically in dogs and cats for cardiovascular support, anesthetic management, diagnostic purposes, and as an antidote for cholinergic agents and toxins. Its use should be targeted to specific clinical indications rather than routine administration.

• Vagally mediated bradycardia (dogs and cats): Used during anesthesia or procedures associated with increased vagal tone to treat clinically significant bradycardia. Treatment of bradyarrhythmias as they occur is preferred over routine prophylactic use.
• Preanesthetic adjunct: Used selectively to reduce vagal tone and, less commonly, to decrease oral and respiratory secretions. Routine use for secretion control has declined with modern anesthetic agents.
• Bradyarrhythmias: Treatment of sinus bradycardia, sinoatrial arrest, and incomplete atrioventricular (AV) block when vagal influence is suspected.
• Cardiopulmonary resuscitation (CPR): Used to block excessive vagal tone and treat bradyarrhythmias during resuscitation efforts in selected dogs and cats.
• Diagnostic use: Employed to help differentiate vagally mediated bradycardia from other causes of slow heart rate based on heart rate response.
• Antidote for cholinergic agents: Used to treat overdoses of cholinergic drugs (e.g., physostigmine) or to mitigate muscarinic adverse effects associated with therapeutic use.
• Organophosphate and carbamate toxicity: Used to control muscarinic signs of poisoning, including salivation, lacrimation, urination, defecation, emesis, bronchoconstriction, and bradycardia.
• Hypersialosis: Used to reduce excessive salivation when clinically indicated.
• Reversal of neuromuscular blockade: Administered in conjunction with anticholinesterase agents (e.g., neostigmine) to prevent or reduce muscarinic adverse effects during reversal of nondepolarizing neuromuscular blockers.

Dosage (Reference)

Dog & Cat

All atropine doses in dogs and cats are considered extra-label. Dose selection should be based on indication, patient status, and cardiovascular monitoring.

Warnings & Precautions

Atropine produces predictable, dose-related anticholinergic effects. In dogs and cats, careful patient selection and indication-based use are essential to avoid clinically significant adverse outcomes.

• Contraindicated conditions: Do not use in dogs or cats with narrow-angle glaucoma, tachycardia secondary to cardiac disease, ileus, urinary retention due to bladder outlet obstruction, hypertrophic or restrictive cardiomyopathy, myocardial ischemia, or unstable cardiac status.
• Alpha-2 agonist–associated bradycardia: Routine use of atropine to treat or prevent bradycardia caused by alpha-2 agonists is discouraged, as it may lead to excessive tachycardia, hypertension, and arrhythmias. Use only when both heart rate and blood pressure are low, or consider alpha-2 reversal.
• Cardiac disease: Anticholinergic-induced tachycardia increases myocardial oxygen demand and may worsen ischemia or precipitate arrhythmias in susceptible patients.
• Gastrointestinal disease or obstruction: Use with extreme caution in animals with GI infections, inflammatory disease, ileus, or suspected obstruction, as atropine decreases GI motility and may prolong toxin or pathogen retention.
• Autonomic or neuromuscular disorders: Use cautiously in dogs and cats with autonomic neuropathy or myasthenia gravis, unless atropine is specifically indicated to counteract adverse muscarinic effects of therapy.
• Hepatic or renal disease: Use cautiously, as altered metabolism or excretion may affect drug response.
• Age-related considerations: Geriatric or debilitated patients may be more sensitive; lower doses are recommended. Atropine may be ineffective in very young puppies and kittens.
• Hyperthermia risk: By reducing salivation and other secretions, atropine may impair heat dissipation; monitor body temperature, especially in warm environments.
• Toxicology considerations: Contraindicated for treatment of isoxazole mushroom poisoning, as anticholinergic effects may worsen clinical signs.

Drug Interactions

Atropine has numerous clinically relevant drug interactions in dogs and cats, primarily related to additive anticholinergic effects, opposing cholinergic activity, or increased cardiovascular risk. When used concurrently with the following agents, careful monitoring and dose adjustment may be required.

• Acetylcholinesterase inhibitors (e.g., edrophonium, neostigmine): May reduce the effects of atropine. Atropine is often intentionally administered immediately prior to these agents to prevent peripheral muscarinic adverse effects.
• Alpha-2 agonists (e.g., dexmedetomidine, medetomidine, xylazine): Concurrent use may cause excessive hypertension, tachycardia, and cardiac arrhythmias. Routine combined use is discouraged.
• Cholinergic agents (e.g., bethanechol, pilocarpine): Concurrent use of muscarinic agonists and antagonists should be avoided due to opposing pharmacologic effects.
• Other anticholinergic drugs (e.g., glycopyrrolate, oxybutynin): Additive anticholinergic effects may increase the risk of ileus, urinary retention, tachycardia, and CNS signs.
• Antihistamines: May enhance anticholinergic adverse effects such as sedation, dry mouth, and GI hypomotility.
• Opioids: Concurrent use may further decrease gastrointestinal motility and increase the risk of ileus or constipation.
• Tricyclic antidepressants: Additive anticholinergic and cardiotoxic effects may occur.
• Phenothiazines and other anticholinergic agents: May exacerbate CNS and cardiovascular adverse effects.
• Metoclopramide and other promotility agents: Atropine may antagonize their prokinetic effects on the gastrointestinal tract.
• MAO inhibitors: Concurrent use may increase the risk of hypertensive reactions.
• Potassium salts (oral solid dosage forms): Reduced GI motility may increase the risk of gastrointestinal irritation or ulceration.

Side Effects & Overdose

Side Effects

Adverse effects of atropine in dogs and cats are extensions of its antimuscarinic pharmacologic actions and are generally dose related. Mild effects may be seen at standard doses, while more severe reactions are associated with high or toxic doses.

• Gastrointestinal effects: Dry mouth (xerostomia), thickened oral and respiratory secretions, dysphagia, constipation, vomiting, and reduced gastrointestinal motility.
• Respiratory effects: Increased viscosity of respiratory secretions, which may impair airway clearance.
• Genitourinary effects: Urinary retention, particularly in animals with pre-existing lower urinary tract disease.
• Central nervous system effects: Stimulation, agitation, drowsiness, ataxia, seizures, or respiratory depression. Sedation or agitation may occur in conscious patients and may affect anesthetic recovery.
• Ophthalmic effects: Mydriasis, cycloplegia, photophobia, and increased intraocular pressure.
• Cardiovascular effects: Sinus tachycardia (often transient), increased myocardial oxygen demand, initial bradycardia at very low doses, hypertension or hypotension, tachyarrhythmias (e.g., PVCs, ventricular tachycardia), and, at excessive doses, circulatory failure.

Overdose

Clinical signs of atropine overdose reflect exaggerated anticholinergic effects. Central nervous system depression and medullary respiratory depression are the most common causes of death in severe intoxication.

• Clinical signs: Severe tachycardia or arrhythmias, hyperthermia, dry mucous membranes, ileus, urinary retention, CNS agitation followed by depression, seizures, and respiratory failure.
• Decontamination: Activated charcoal and saline cathartics may be considered following recent oral ingestion.
• Management: Supportive care is the mainstay of treatment, including maintenance of hydration, respiratory support, and management of cardiac arrhythmias. Avoid phenothiazines, which may worsen anticholinergic effects.
• Physostigmine: Use is controversial and generally reserved for animals with severe agitation or life-threatening supraventricular tachycardia or sinus tachycardia.
• Advanced support: Standard shock therapy may be required. Atropine is not removed by dialysis.

Key Notes

Practical clinical points for optimizing the safe and effective use of atropine in dogs and cats, without repeating information addressed in other sections:

• Indication-driven use: Atropine should be administered for clearly defined clinical indications rather than as a routine or prophylactic medication.
• Heart rate interpretation: A meaningful increase in heart rate after atropine administration supports a vagal component to bradycardia and can help guide further diagnostic or therapeutic decisions.
• Short duration: The relatively brief duration of action may necessitate repeat dosing or alternative agents when sustained anticholinergic effects are required.
• Choice of anticholinergic: When prolonged effect with less tachycardia is desired, glycopyrrolate may be a more appropriate alternative.
• Secretions vs airway protection: Thickened respiratory secretions may impair airway clearance; ensure adequate humidification and airway management when atropine is used perioperatively.
• Toxin management limits: In cholinergic toxicoses, atropine improves muscarinic signs only and does not address nicotinic or central nervous system effects.
• Monitoring priority: Continuous cardiovascular monitoring is particularly important immediately after IV administration due to rapid onset of effects.